Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure's preclinical work on next-gen antibody
Right on the heels of nailing a $40 million upfront for its oncology R&D collaboration deal with Eli Lilly and bringing its tally of cash raised to $180 million with an ambitious venture round, Yale spinout NextCure has laid the scientific foundation for the immuno-oncology company in a new preclinical study just published in Nature Medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
